Okada D R, Johnson G, Liu Z, Hocherman S D, Khaw B A, Pak K Y, Okada R D
University of Tulsa and the William K. Warren Medical Research Institute, University of Oklahoma Health Sciences Center, Tulsa, Okla.
J Nucl Cardiol. 2003 Mar-Apr;10(2):168-76. doi: 10.1067/mnc.2003.1.
Technetium-99m glucarate is a myocardial infarct-avid imaging agent. Recent conflicting and inconclusive reports have suggested that the agent may be taken up by ischemic but viable myocardium. The purposes of this study were (1) to determine conclusively whether there is Tc-99m glucarate uptake in ischemic viable myocardium and (2) to investigate the potential mechanisms for such uptake by studying components of ischemia, namely, low flow, hypoxia, and aglycemia.
Rat hearts were isolated and perfused in a modified Langendorff preparation with a crytalloid perfusate. Tc-99m glucarate was studied in control (n = 6), low-flow (n = 5), hypoxic (n = 5), and aglycemic (n = 5) conditions. The experimental protocol consisted of 20-minute baseline (12 mL/min flow) and 20-minute treatment (low flow at 1 mL/min, hypoxia, or aglycemia), followed by tracer uptake (20 minute) and washout (20 minutes). Activity was monitored with a sodium iodide detector. The tracer was delivered continuously over a 20-minute uptake period. The injected dose was 150 micro Ci (5.6 MBq). Hemodynamics were monitored throughout. Triphenyltetrazolium chloride staining was used to assess myocardial viability. There was no evidence of myocardial necrosis. Low flow tended to delay tracer uptake compared with control for the first 10 minutes, but this did not reach statistical significance. Low flow increased end fractional retention significantly compared with control (mean +/- SEM, 59.0% +/- 0.9% peak vs 41.2% +/- 1.4%, respectively; P <.05). Hypoxia resulted in a trend toward increased uptake; however, this was significant only at one early time point during the uptake phase. Retention in the hypoxia group was similar to control. Tc-99m glucarate uptake was significantly increased in aglycemia from 16 minutes to peak compared with control (1.36% +/- 0.71% injected dose per gram vs 0.91% +/- 0.37% injected dose per gram, respectively; P <.05). Aglycemia produced significantly higher end fractional retention compared with control (51.6% +/- 1.8% peak vs 41.2% +/- 1.4%, respectively; P <.05).
Tc-99m glucarate myocardial retention is increased in the setting of ischemia, even in the absence of necrosis. This increased retention is not due to hypoxia. Furthermore, the retention is only partially explained by tissue hypoglycemia. Thus low flow per se appears to have a role in this increased retention, probably as a result of delayed flow-dependent washout.
锝-99m葡糖醛酸是一种对心肌梗死具有亲合力的显像剂。近期相互矛盾且尚无定论的报告表明,该显像剂可能被缺血但存活的心肌摄取。本研究的目的是:(1)明确缺血存活心肌中是否存在锝-99m葡糖醛酸摄取;(2)通过研究缺血的组成部分,即低灌注、缺氧和低血糖,探讨这种摄取的潜在机制。
将大鼠心脏分离后,在改良的Langendorff装置中用晶体灌注液进行灌注。在对照(n = 6)、低灌注(n = 5)、缺氧(n = 5)和低血糖(n = 5)条件下研究锝-99m葡糖醛酸。实验方案包括20分钟的基线期(流量为12 mL/分钟)和20分钟的处理期(低灌注,流量为1 mL/分钟、缺氧或低血糖),随后是示踪剂摄取期(20分钟)和洗脱期(20分钟)。用碘化钠探测器监测活性。在20分钟的摄取期内持续给予示踪剂。注射剂量为150微居里(5.6 MBq)。全程监测血流动力学。用氯化三苯基四氮唑染色评估心肌存活情况。未发现心肌坏死的证据。与对照组相比,低灌注在最初10分钟倾向于延迟示踪剂摄取,但未达到统计学意义。与对照组相比,低灌注显著增加了终末分数潴留(分别为平均±标准误,峰值时59.0%±0.9%对41.2%±1.4%;P<.05)。缺氧导致摄取增加的趋势;然而,这仅在摄取期的一个早期时间点具有统计学意义。缺氧组的潴留与对照组相似。与对照组相比,低血糖时锝-99m葡糖醛酸摄取从16分钟到峰值显著增加(分别为每克注射剂量的1.36%±0.71%对0.91%±0.37%;P<.05)。与对照组相比,低血糖产生的终末分数潴留显著更高(分别为峰值时51.6%±1.8%对41.2%±1.4%;P<.05)。
即使在无坏死的情况下,缺血时锝-99m葡糖醛酸心肌潴留也会增加。这种增加的潴留并非由缺氧所致。此外,组织低血糖仅部分解释了这种潴留。因此,低灌注本身似乎在这种增加的潴留中起作用,可能是由于依赖血流的洗脱延迟所致。